# Efficacy and Safety of HRS-1780 Tablets and Henagliflozin Proline Tablets in Patients With Chronic Kidney Disease

Study · id `cardio:ct-nct06221059` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06221059](<https://clinicaltrials.gov/study/NCT06221059>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06221059

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 181 participants.

## Technical summary

Registry record NCT06221059. Randomized; triple masking; primary purpose treatment. Start 2024-03-02 (actual); primary completion 2025-03-05 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 181 participants (enrolled count; ClinicalTrials.gov record NCT06221059, source copy `cardio:ctgov-nct06221059-2025-12-01`, retrieved 2026-10-26)
- Started: 2024-03-02 (actual) (ClinicalTrials.gov record NCT06221059, source copy `cardio:ctgov-nct06221059-2025-12-01`, retrieved 2026-10-26)
- Primary completion: 2025-03-05 (actual) (ClinicalTrials.gov record NCT06221059, source copy `cardio:ctgov-nct06221059-2025-12-01`, retrieved 2026-10-26)
- Completion: 2025-06-24 (actual) (ClinicalTrials.gov record NCT06221059, source copy `cardio:ctgov-nct06221059-2025-12-01`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT06221059, source copy `cardio:ctgov-nct06221059-2025-12-01`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06221059-2025-12-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of HRS-1780 Tablets and Henagliflozin Proline Tablets in Patients With Chronic Kidney Disease
- Condition: Chronic Kidney Disease
- Intervention (Drug): HRS-1780 tablet；Henagliflozin Proline tablet；HRS-1780 tablet placebo ；Henagliflozin Proline tablet placebo
- Lead sponsor: Shandong Suncadia Medicine Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Shandong Suncadia Medicine Co., Ltd. (`cardio:org-shandong-suncadia-medicine-co-ltd`)

## Provenance

Content hash: cbd7f4af72dacef3379edc3a8972f968f9a34effe8c5cb9227166b6edcb55588
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
